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Abstract
Background: Kidneys have an important function in blood pressure (BP) regulation and elevated
BP may lead to kidney failure. Chr2p12-p13 region linked to BP traits in multiple studies harbours
a potential candidate for BP and renal function, N-acetyltransferase 8 (NAT8) expressed in embryonic
and adult kidney and associated with nephrotoxicity response.
Methods/Results: We report the first study exploring NAT8 as a potential candidate gene for
blood pressure and kidney function. The resequencing (n = 42, random Estonian samples) identified
15 NAT8 polymorphisms, including 6 novel variants. The diversity of NAT8 5' upstream region (π/
bp = 0.00320) exceeded up to 10 times the variation in the NAT8 genic region (π/bp = 0.00037) as
well as the average variation (π/bp = 0.00040) for the promoters of 29 reference genes associated
with hypertension. We suggest that a potential source for such high variation could be an active
gene conversion process from NAT8B duplicate gene to NAT8. Similarly to NAT8, several reference
genes with the most variable upstream regions have also duplicate copies. The NAT8 promoter
SNPs were targeted with pilot quantitative association studies for blood pressure (n = 137, healthy
unrelated individuals) and for the index of kidney function – estimated glomerular filtration rate
(eGFR; n = 157 hypertensives with and without nephropathy). Minor alleles of these
polymorphisms revealed a significant protective effect against elevated systolic BP as well as kidney
failure in hypertension patients (p < 0.05; linear regression model, addictive effect).
Conclusion: The full resequencing and pilot association study of a novel positional candidate gene
for blood pressure and renal function, human N-acetyltransferase 8, suggested a contribution of
highly variable NAT8 promoter polymorphisms in determination of systolic blood pressure and
eGFR. Based on in silico analysis, we raise the hypothesis that the alternative SNP alleles of the NAT8
upstream region may have differential effect on gene expression.
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Background
Twin studies have shown that approximately half of the
inter-individual variance in blood pressure (BP) level is
heritable [1,2]. As distinctive for complex diseases, patho-
logically high BP diagnosed as essential hypertension
(repeated systolic and diastolic BP readings > 140 and/or
> 90 mmHg) evolves in association with genetic predispo-
sition and personal life-style. Identification of the muta-
tions behind Mendelian forms leading to hypo- or
hypertension has highlighted the central role of the renal
metabolic pathways in blood pressure regulation [3].
Consistently, depending on the severity and duration of
the hypertension, the patients may develop morphologi-
cal changes in vasculature of kidneys followed by the pro-
gression renal failure [4-6]. In the other way around, it has
also been proposed that the defective embryonic develop-
ment of the kidney or loss of existing nephrons may act as
a predisposing factor for primary hypertension [7-10].
Genome-wide linkage studies [11] have identified the
short-arm of human Chr2 as one of the four major
genomic regions to be responsible for BP regulation and
therefore hold a risk for essential hypertension. Several
candidate genes (ADD2; SLC8A1) from this region have
been proposed and investigated in detail to play a role in
the aetiology of essential hypertension [12,13]. For this
study we screened the reported linkage regions at Chr2 for
novel BP regulating genes involved in kidney function
and renal metabolic pathways. Within the window of 10
Mb from the four reported linkage peaks [11] we have
identified at 2p13.1-p12 a novel functionally relevant
candidate gene N-acetyltransferase 8 (NAT8) that is highly
expressed in normal human embryonic kidney and liver.
NAT8 protein has been suggested to play an important
role in development and maintenance of the structure and
function in adult kidney and liver [14]. Although exact
function of the NAT8 is unknown, its expression profile is
related to detoxification pathways in kidney [15].
In the present study, we have carried out the resequencing
of human NAT8  gene followed by a pilot association
study of the common NAT8  sequence variation with
blood pressure measurements and the index of kidney
function. We show that most of the NAT8 variation is har-
boured in the 5'UTR and upstream regions, which is asso-
ciated with both, systolic blood pressure levels and the
estimated glomerular filtration rate (eGFR).
Methods
Study Population
The study has been approved by the Ethics Committee on
Human Research of University of Tartu, Estonia (permis-
sions no 122/13,22.12.2003; 137/20, 25.04.2005). The
initial study for resequencing (n = 42) and the association
studies (detailed description found below) were carried
out using samples of recruited individuals from the Esto-
nian population, classified as a typical North-European
population based on its genetic composition [16]. All par-
ticipating individuals gave their informed consent prior to
their inclusion into the study.
Resequencing
The sequence of the human NAT8 genomic region has
been obtained from NCBI GeneBank database. As NAT8
possesses a duplicate gene NAT8B located about 58 Kb
downstream from NAT8, the design of the amplification
of human NAT8 gene involved two steps (long-range PCR
and nested-PCR) (Figure 1a). Alignments between NAT8/
NAT8B and their flanking areas (web-based global align-
ment tool CLUSTALW [17]) revealed a high nucleotide
homology between extended genomic regions. The for-
ward primer for NAT8 was positioned within a 313 bp
NAT8-specific insertion (Figure 1b). The Primer3 primer
designing software [18] was used to search for the match-
ing reverse primer from the region upstream of NAT8,
where the sequence homology with NAT8B region did not
continue (> 2722 bp upstream; Figure 1b). The unique-
ness of long-range PCR primers was checked using BLAST
[19]. PCR reactions were performed using Long PCR
Enzyme Mix (MBI Fermentas, Vilnius, Lithuania) and
Smart-Taq Hot DNA polymerase (Naxo, Estonia) accord-
ing to the standard protocol recommended by the manu-
facturers. Detailed conditions for long-range (10341 bp)
and nested (2322 bp) PCR, product purification, sequenc-
ing, sequence contig assembly and polymorphism identi-
fication are described in detail elsewhere [20]. The
resequenced region covered 2185 bp including the entire
NAT8 (1569 bp) as well as 541 bp of the 5' upstream and
75 bp of the 3' downstream regions. All primers used for
the NAT8 PCR amplification and resequencing are listed
in Table 1.
In the extended association study of the 5'upstream SNPs,
only the sequencing primers 4F and 4R were used. For the
comparison of sequence diversity parameters, we rese-
quenced (n = 14) the promoter regions (+100 bp up to -
500 bp relative to mRNA transcription initiation site) for
29 previously established blood pressure associated genes
from literature: ACE, ADD1, ADD2, AGT, AGTR1, AGTR2,
KCNJ1, CYP17A1, NPR1, CLCNKA, HSD11B1, CYP11B2,
CLCNKB, KLK1, NPR2, BSND, NR3C2, CYP21A2, SAH,
SGK, SLC12A3, SCNN1A, IL1A, SLC14A2, SLC22A2,
REN, ATP1A, SCNN1B and  SLC8A1  (primers used for
PCR and resequencing, see additional file 1: Primers).
Subjects for Association Studies
Association study for blood pressure
Long-term blood donors (n = 137; 76 males, 61 females;
age 40 ± 7.8 years; BMI 25 ± 2.6) were recruited in the
framework of HYPEST study (participation rate 51.5%;BMC Medical Genetics 2008, 9:25 http://www.biomedcentral.com/1471-2350/9/25
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(a) The structure of NAT8/NAT8B cluster: NAT8/NAT8B location in chromosome 2p13.1-p12; (b) Schematic presentation of the  alignment of NAT8/NAT8B and their flanking regions and the positioning of NAT8-specific PCR primers; (c) NAT8 resequencing  results and SNP positions compared to dbSNP database records; (d) Missing Binding Sites for Transcription Factors (TFBS) on  chromosomes carrying the minor alleles of SNPs -911, -1151 and -1153 Figure 1
(a) The structure of NAT8/NAT8B cluster: NAT8/NAT8B location in chromosome 2p13.1-p12; (b) Schematic 
presentation of the alignment of NAT8/NAT8B and their flanking regions and the positioning of NAT8-specific 
PCR primers; (c) NAT8 resequencing results and SNP positions compared to dbSNP database records; (d) 
Missing Binding Sites for Transcription Factors (TFBS) on chromosomes carrying the minor alleles of SNPs -
911, -1151 and -1153. "S" – singleton polymorphisms.
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Org et al., unpublished data) from the North Estonian
Blood Center [21] coordinating the blood donation in
northern, eastern, and western Estonia, and the Blood
Centre of the Tartu University Clinics [22] coordinating
the blood donation activity in central and southern Esto-
nia. The exclusion criteria for donors included cardiovas-
cular diseases, diabetes and antihypertensive treatment
ascertained by confidential self-reported signed question-
naires and medical examination. Both Blood Centres have
standardized protocols for measuring blood pressure by
responsible trained clinicians. After a rest in a sitting posi-
tion, the blood pressure reading of a donor was obtained
during each visit to the Blood Donation Centre. All
recruited individuals possess a documented history of
multiple systolic and diastolic blood pressure (SBP, DBP)
readings (on average 4 readings per individual, range
2–14) during 3 ± 2.5 years (range 1–7 years). Most of the
BP measurements per subject have been obtained using a
standard mercury column sphygmomanometer and size-
adjusted cuffs. Occasionally, outside of blood donation
centres BP of the participants was measured by oscillom-
etric method using NAIS DIAGNOSTEC blood pressure
watch (Matsushita Electronic Works) after a rest in a sit-
ting position and with the arm placed at the heart level.
No systematic deviation was observed between the two
devices. The BP parameters across the whole cohort study
group were as following: SBP 134.2 ± 11.5 mmHg within
a range of 113.5 – 171 mmHg; and DBP 84.6 ± 7.6 mmHg
within a range of 65.5 – 110 mmHg. Quantitative analysis
was performed with a calculated median of a subject's BP
readings adjusted to age and sex as co-variables.
Association study for estimated glomerular filtration rate (eGFR)
The study group of long-term essential hypertension (EH)
patients (n = 157; 78 males, 79 females; age at the time of
EH diagnosis 47 ± 9.7 years; age at recruitment 59 ± 9
years; BMI 28 ± 3.8) without and with hypertensive neph-
ropathy were recruited (participation rate 42.3%) by
blood pressure specialists during the patients' ambulatory
visit or hospitalization at the North Estonia Medical
Center, Centre of Cardiology (cardiologist M.V.) or at the
Cardiology (coordinated by G.V.) and Internal Medicine
Clinics (nephrologist M.R.), Tartu University Hospital,
Estonia. The selection criteria for the study group were as
following:
- Long term (mean duration 12.5 y) essential hyperten-
sion diagnosed by a clinical specialist (SBP > 140 mmHg,
DBP > 90 mmHg).
- Exclusion of patients with diabetes and primary renal
failure by a clinical specialist
- All recruited hypertension patients received antihyper-
tensive treatment
Diagnose of hypertensive nephropathy was assigned by
nephrologists (M.R.) based on longstanding blood pres-
sure elevation together with proteinuria and presence of
progressive chronic kidney disease. Differential diagnosis
was established using methods per exclusionem i.e. the
patients possessed no symptoms of glomerulonephritis,
systemic diseases, amyloidosis or other glomerulopathies,
confirmed by diagnostic labororatory tests.
The venous blood for serum biomarker analysis was
drawn in the morning after an overnight fast. Urea (meas-
urement uncertainty 9.7%), creatinine (m.u. 17.2%) and
albumine (m.u. 6.9%) in the serum were measured by
standardized assays (Cobas Integra 800® analytical plat-
form, Roche Diagnostics, Inc.) at the United Laboratories,
Tartu University Clinics [22] or at the Diagnostics Divi-
sion Laboratory, the North Estonia Medical Centre [23].
The tests of for the serum biomarkers have been accred-
ited by the Estonian Accreditation Centre [24] according
to the standards of the European co-operation for Accred-
itation [25]. Measurement uncertainty was estimated
using EURACHEM guidelines [26]. It is defined as the
parameter associated with the result of a measurement
that characterizes the dispersion of the values that could
reasonably be attributed to the measurand (e.g. the con-
centration of a biomarker).
Table 1: PCR and resequencing primers for human NAT8
Primer ID Primer sequence 5'-3'
NAT8 resequencing
Long-range PCR 
primers
NAT8_10kb_F TGTAATCCCACACTTTTAGAGGCCAAG
NAT8_10kb_R GAGTAGGTAAACAAAGCAGCCAGGAA
Nested PCR 
primers
NAT8_2kb_F GCAAAATTGCTGACTTCAGACTC
NAT8_2kb_R CAACAGCCAGAACACACACAAG
Sequencing 
primers
NAT8_SEQ_1F TGCAACATTATGCTGGCACT
NAT8_SEQ_2F CAGACTCAGCCACCCAGAAG
NAT8_SEQ_3F AGGGTCAGAAAGACCTGCATT
NAT8_SEQ_4F GCATCCAGGAGATACCGTCT
NAT8_SEQ_1R ATTGCTGAAGCTGCCTCGAAC
NAT8_SEQ_2R AGGTAGGTGCCCCCTCAAT
NAT8_SEQ_3R CCTGAACAGGCAAGAGAGGT
NAT8_SEQ_4R GTCAAGCCGAATGTCAACCTBMC Medical Genetics 2008, 9:25 http://www.biomedcentral.com/1471-2350/9/25
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Kidney function was evaluated using estimated glomeru-
lar filtration rate (eGFR), the most recommended overall
index of kidney function in health and disease [27]. The
formula [28] includes both, demographic (age, sex, race)
and blood serum (urea – SUN [mg/dl], creatinine – PCr
[mg/dl], albumin – Alb [g/dl]) variables.
eGRF (ml/min/1,73 m2) = 170× (PCr)-0,999 × (Age)-0,176 ×
(0,762 if patient is female) × (SUN)-0,17 × (Alb)+0,318
A decrease of eGFR below 60 ml/min/1.73 m2 precedes
the onset of kidney failure (K/DOQI 2002). The distribu-
tion of eGFR values for our study population was 72 ±
28.5 (range 5 – 143).
Statistical analysis
Methods used for Hardy-Weinberg equilibrium estima-
tions, sequence diversity calculations and in silico predic-
tion of transcription factor binding sites are described in
detail elsewhere [29,30]. Quantitative genetic association
analyses for blood pressure and serum biomarkers were
performed with association analysis toolset PLINK [31].
Association was tested using linear regression analysis
with additive effect model and likelihood-ratio test (LRT)
with age, sex and BMI as co-variables. Statistical signifi-
cance for the different distribution of the quantitative
measurements (BP, GFR) in two subgroups based on the
genotype was verified using non-parametric Mann-Whit-
ney two-sided U-test performed with a web-based inter-
face [32]. In all computed statistical tests a p-value < 0.05
was considered statistically significant and p < 0.1 as sug-
gestive.
Results
Detailed diversity patterns of NAT8 by resequencing
To uncover the detailed genetic variation of a putative
human blood pressure candidate gene NAT8 (N-acetyl-
transferase 8; 2p13.1-p12) we resequenced the gene in a
random Estonian population sample (n = 42). The ana-
lyzed region (1569 bp of the entire NAT8; 541 bp of 5'
upstream and 75 bp of 3' downstream) harboured 15
SNPs including 10 rare (Minor allele frequency, MAF <
10%) and five common (MAF > 10%) polymorphisms
(Table 2). Nine SNPs (n = 6 in 5'upstream region; n = 1 in
intron 1, exon 2 and 3'downstream region) were previ-
ously characterized in dbSNP database, including five
HAPMAP SNPs (rs482951, rs2280506, rs2280507,
rs6744273, rs13538). Six rare variants are novel, neither
represented in dbSNP nor reported elsewhere: one SNP in
untranslated exon 1, one in intron 1 and four nonsynon-
ymous substitutions in exon 2. The alignment of NAT8
protein sequences (Figure 2) of several vertebrate species
(Pan troglodytes, Mus musculus, Rattus norvegicus, Xenopus
tropicalis) indicated that the human polymorphic amino
acid positions are not conserved in evolution. Thus we did
not include these SNPs for further association study.
The NAT8 resequencing data deviated strongly from the
polymorphism pattern in public dbSNP database [33]
with 39 SNP entries for NAT8  region (Figure 1c). The
higher number of SNPs in dbSNP might represent paralo-
gous sequence variants (PSVs) between NAT8  and its
duplicate gene NAT8B  as all the unidentified dbSNP
entries co-located with the sequence positions where
NAT8 and NAT8B diverge (see additional file 2: Align-
ment).
Table 2: NAT8 genomic region SNPs identified by resequencing in random Estonian population samples (n = 42)
Region Locationa dbSNP rs# SNPb Codon change MAF
5' upstream -1255 rs4852954 T/C - 0.25
-1153 rs4852953 A/G - 0.226
-1152 rs4852952 C/T - 0.226
-1041 rs4852951 G/C - 0.238
-911 rs2280506 T/C - 0.083
-803 rs2280507 C/T - 0.071
Exon1 -763 - T/C - 0.012 (S)
Intron1 -365 rs6744273 A/G - 0.071
-222 - T/G - 0.012 (S)
Exon2 41 - C/T Arg-His 0.024
218 - G/A Ala-Val 0.012 (S)
362 - A/G Met-Thr 0.012 (S)
390 - G/T Pro-Pro 0.012 (S)
428 rs13538 A/G Phe-Ser 0.167
3'downstream 859 rs1879662 G/A - 0.071
Abbreviations: MAF, minor allele frequency; S, singletons
aLocation relative to ATG
bMajor/minor alleleBMC Medical Genetics 2008, 9:25 http://www.biomedcentral.com/1471-2350/9/25
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Direct estimation of per-site heterozygosity (π) was
derived from the average pairwise sequence difference.
The NAT8 gene (1569 bp; π/bp = 0.00037) and mRNA
(953 bp; (π/bp = 0.00045) exhibit two times lower
sequence diversity compared to a data set of 74 genes [34]
(π/bp = 0.00080 for European Americans; Table 3).
Tajima's D (DT) statistic was used to estimate the differ-
ence between the parameters π and θ, representing the
expected per-site heterozygosity based on the number of
segregating sites. In case of neutrality, π equals θ and thus
DT statistic equals zero. For NAT8 coding region, the cal-
culated negative DT values refer to the excess of rare SNPs
The alignment of NAT8 protein sequences: 1- Homo sapiens, 2- Pan troglodytes, 3- Mus musculus, 4- Rattus norvegicus, 5-Xenopus  tropicalis Figure 2
The alignment of NAT8 protein sequences: 1- Homo sapiens, 2- Pan troglodytes, 3- Mus musculus, 4- Rattus nor-
vegicus, 5-Xenopus tropicalis. Arrows pointing at polymorphic amino acid positions (14 Arg-His, 73 Ala-Val, 121 Met-Thr, 
130 Pro-Pro, 143 Phe-Ser).BMC Medical Genetics 2008, 9:25 http://www.biomedcentral.com/1471-2350/9/25
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suggesting a purifying selection pressure. In contrast, the
NAT8  5'upstream region exhibits approximately eight
times higher diversity (π/bp = 0.00320; Table 3) and a
positive DT value indicating an excess of common SNPs.
Accordingly, four of the five NAT8 SNPs with minor allele
frequency > 10% are located in the upstream region. Nota-
bly, this high diversity is uncommon in the dataset of pro-
moter regions (+100 bp to -500 bp relative to mRNA
transcription start) of 29 previously studied blood pres-
sure genes resequenced to compare with NAT8 (Table 3).
The diversity level of NAT8  upstream area (6 SNPs)
exceeded about eight times the average of 29 reference
genes (π/bp = 0.00320 versus π/bp = 0.0004). Of the 29
studied gene upstream regions, 17 (59%) had no SNPs, in
the rest of the genes (n = 12) the number of SNPs ranged
from one to four with the heterozygosity parameter (π)
being 0.00023-0.0017. Interestingly, similarly to NAT8,
several genes with the most variable upstream regions
(CYP11B2, IL1A, SLC14A2) have also duplicate copies.
Association study of NAT8 5' upstream SNPs with blood 
pressure and eGFR
A  NAT8  5'upstream putative promoter region [SNPs -
1255 (T/C), rs4852954; -1153 (A/G), rs4852953; -1152
(C/T), rs4852952; -1041 (G/C), rs4852951; -911 (T/C),
rs2280506 and -803 (C/T), rs2280507] was targeted in
association studies for BP and estimated glomerular filtra-
tion rate (eGFR). Despite close vicinity, these SNPs form
two distinct allelic association blocks: from -1225 to -
1041 and from -911 to -365 (Figure 3). Notably, the latter
region is also in LD with the 3' downstream SNP (+859 G/
A; rs1879662). We used median values of systolic and
diastolic blood pressure (SBP, DBP) readings in a cohort
of long-term healthy Estonian donors (n = 137) with no
history of cardiovascular diseases and respective treat-
ments. SBP was significantly associated with NAT8 SNPs -
803 (C/T) and -911 (T/C) using LRT (p = 0.028) and lin-
ear regression model (additive effects of allele dosage; p =
0.015) tests (Table 4). The significant negative regression
coefficient (-5.034) referred to the association of the
minor alleles of SNP -803/-911 with lower SBP values and
indicated that these variants may possess a potential pro-
tective effect towards hypertension. Indeed SBP was signif-
icantly (p = 0.04; Mann-Whitney U test) lower by average
5 mmHg for the carriers of the minor alleles (median 131
mmHg; mean 130.5 ± 10.0; n = 33) compared to the
major allele homozygotes (median 135 mmHg; mean
135.5 ± 11.7; n = 104) for SNPs -803/-911 (Figure 4a),
supporting a protective effect of these alleles against blood
pressure elevation. Association analysis of SBP with other
upstream SNPs and of DBP with any NAT8 SNPs did not
reveal any statistical significance (p = 0.1).
We further tested the association of NAT8 upstream SNPs
with the reduction of kidney function as a consequence of
essential hypertension using an Estonian cohort of long-
term hypertension patients without and with hyperten-
sive nephropathy. Linear regression analysis (additive
model) and LRT test detected significant (SNP-803 and
SNP-1041; p < 0.05) and borderline (p ≤ 0.08) associa-
tions of NAT8 upstream SNPs with eGFR estimates reflect-
ing the efficiency of kidney function (Table 4). Significant
Table 4: P-values from association tests of NAT8 upstream SNPs: 
linear regression (additive model) adjusted for age, gender and 
BMI
Blood pressure
SNP ID SBP DBP eGFR
-803 (C/T) 0.015 0.157 0.042
-911 (T/C) 0.015 0.100 0.060
-1041 (G/C) 0.519 0.943 0.050
-1152 (C/T) 0.373 0.828 0.081
-1153 (A/G) 0.373 0.828 0.081
-1255 (T/C) 0.659 0.870 0.070
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood 
pressure; e GFR, estimated glomerular filtration rate; p < 0.05; p ≤ 
0.1.
Table 3: Diversity parameters for resequenced NAT8 gene and 
promoter regions of 29 genes associated with blood pressure 
determination
Region SNPs πθ DT
A. NAT8 region
Gene (1569 bp) 9 0.00037 0.00102 -1.58
mRNA (953 bp) 6 0.00045 0.00127 -1.49
Promoter (600 bp)a 6 0.00320 0.00221 1.05
B. Promoter regions (600 bp)a of 29 blood pressure associated genesb
AGTR1 1 0.00082 0.00043 1.47
CYP17A1 2 0.00058 0.00043 0.57
CLCNKA 2 0.00081 0.00086 -0.11
CYP11B2 3 0.00168 0.00085 2.02
NPR2 1 0.00042 0.00043 -0.018
BSND 2 0.00023 0.00043 -0.74
SAH 2 0.00071 0.00087 -0.38
SGK 1 0.00079 0.00043 1.36
SLC12A3 1 0.00075 0.00043 1.216
SCNN1A 3 0.00167 0.00128 0.721
IL1A 2 0.0017 0.00086 2.02
SLC14A2 4 0.00133 0.00085 1.17
Abbreviations: π, estimate of nucleotide diversity per site from 
average pairwise difference among individuals; θ, estimate of 
nucleotide diversity per site from number of segregating sites; DT, 
value of Tajima's D statistics expressing the difference between π and 
θ estimates
aRegion between -500 bp and +100 bp relative to mRNA 
transcription start point
bNo SNPs were detected in Estonian sample by resequencing the 
promoter regions for ACE, ADD1, ADD2, AGT, AGTR2, KCNJ1, NPR1, 
HSD11B1, CLCNKB, KLK1, NR3C2, CYP21A2, SLC22A2, REN, ATP1A1, 
SCNN1B, SLC8A1 genesBMC Medical Genetics 2008, 9:25 http://www.biomedcentral.com/1471-2350/9/25
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positive linear regression coefficients indicated the associ-
ation of SNP-803 (10.7) and SNP-1041 (6.4) with higher
GFR values. The distribution of eGFR values for heterozy-
gotes of SNP -803 (median 83.3; mean 82 ± 21.5; n = 33)
and SNP -1041 (median 80.5; mean 77 ± 28; n = 90) was
significantly higher (Mann-Whitney U test, p = 0.04 and p
= 0.02) than for wild-type homozygotes (SNP -803:
median 71.9; mean 70 ± 29.7, n = 124; SNP -1041:
median 68.3; mean 66 ± 28; n = 67) on average 12 and 11
GFR units, respectively (Figure 4b).
Functional significance of NAT8 5'upstream SNP alleles
Possible functional significance of NAT8 upstream SNP
alternative alleles was targeted with the in silico transcrip-
tion factor binding site (TFBS) prediction using MatIn-
spector [35] software. Several potential TFBSs within
predicted classical promoter region (+100 to -500 bp rel-
ative to mRNA transcription start) are missing on the
chromosomes that carry the minor alleles for NAT8
upstream SNPs -911 (major allele T/minor allele C), -
1152 (C/T) and -1153 (A/G) (Figure 1d). Compared to
the common T variant, the C allele of SNP -911 lacks
potential binding sites for seven competing or co-activat-
ing TFs, including factors involved in inflammatory, cardi-
ovascular or renal function: oestrogen related receptor
(ERR) [36], RAR-related orphan receptor alpha1 (RORA)
[37], HMG box-containing protein 1 (HBP1) [38],
nuclear factor kB (NF-kB)/c-rel [39]. Allele- specific bind-
LD structure of the resequenced NAT8 genomic region shown as r2-blot Figure 3
LD structure of the resequenced NAT8 genomic region shown as r2-blot. Upper white bar depicts the positions of 
identified SNPs (Table 2) relative to the location of NAT8 gene ATG (A denoted as +1). Singleton polymorphisms were 
excluded from calculations.
0                           1  
r2BMC Medical Genetics 2008, 9:25 http://www.biomedcentral.com/1471-2350/9/25
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Notched box plots for the distribution of (a) systolic blood pressure (SBP) readings; and (b) estimated glomerular filtration rate  (GFR) values for the major allele homozygotes and the minor allele carriers of NAT8 promoter SNPs Figure 4
Notched box plots for the distribution of (a) systolic blood pressure (SBP) readings; and (b) estimated glomer-
ular filtration rate (GFR) values for the major allele homozygotes and the minor allele carriers of NAT8 pro-
moter SNPs. The boxes represent the 25th and 75th percentiles. The median is denoted as the line that bisects the boxes. The 
whiskers are lines extending from each end of the box covering the extent of the data on 1.5 × interquartile range. Circles rep-
resent the outlier values. P-values from Mann-Whitney U-test are shown, applied to test the statistical difference in the distri-
butions of SBP or GFR estimates between two groups.
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ing of ERR was confirmed by another TFBS prediction pro-
gram AliBaba 2.1. [40]. Minor combinatory variant (T-G)
for neighbouring SNPs -1152/-1153 miss two potential
TFBSs, one for serum response factor (SRF) and the other
for myeloid zinc finger protein (MZF1) located on the
opposite strands. SRF is a transcription factor conserved
from flies to humans and shown to regulate coordinated
gene expression in cardiac and vascular smooth muscle
cell differentiation [41].
Discussion
We report the first study targeting human N-acetyltrans-
ferase 8 (NAT8) as a potential blood pressure (BP) and
kidney function associated gene. Although the knowledge
about NAT8 is scarce, it was shown to be highly expressed
in developing as well as adult human kidney and liver
[14]. A recent study associated NAT8 expressional profile
with nephrotoxicity response [15]. Kidney function has
been associated with BP from two complimentary view-
points: (1) link between elevated blood pressure and risk
for kidney failure [4,6]; and (2) link between renal struc-
tural/functinonal abnormalities developed during intrau-
terine life as susceptibility to hypertension in adult life
[7,10]. In listing the candidate genes for association stud-
ies of human blood pressure traits, the genes protecting
and contributing to normal fetal renal programming have
often been overlooked as potential susceptibility factors.
We showed that the putative upstream NAT8 promoter
region is highly diverse compared to the gene's coding
region, as well as to the promoters of BP-associated refer-
ence genes resequenced for comparison. High diversity
may indicate the lack of selective constraint and/or the
maintenance of several functioning promoter variants
with differential effect on gene expression. For a number
of genes shown to contribute to blood pressure regula-
tion, the promoter polymorphisms have been associated
with the diagnosis of hypertension. Examples of experi-
mentally confirmed differential effects of alternative alle-
les on promoter activity are CYP11B2  [42-44],  NPR1
(reviewed in [45]), SCNN1A [46] and AGT [47].
In a pilot association study based on a random Estonian
population cohort we identified an association between
NAT8 promoter SNPs and systolic BP. Consistently, in a
separate cohort of essential hypertension patients the
same markers showed association with estimated glomer-
ular filtration rate (eGFR). Interestingly, the minor alleles
of the same SNPs reveal protective effects towards both,
the elevated BP and the risk of kidney failure as the com-
plication to high blood pressure. We are aware that the
results of these pilot association studies may be biased
due to phenotypic misclassification and/or may be under-
powered due to limited sample sizes. Also, multiple test-
ing tends to inflate type 1 error rates. Another limitation
may be the lack of sensitivity of the eGFR calculations
based on serum creatinine instead of the actual GFR val-
ues obtained from measurements using an exogenous fil-
tration marker. Thus, replication of the association of
NAT8 with SBP and eGFR in other study populations, as
well as functional experiments addressing the effect of the
alternative promoter variants are required to ultimately
determine the role of this gene in blood pressure regula-
tion and kidney function. While evaluating the data from
the association studies, one also has to keep in mind that
both BP regulation and kidney metabolic function are
complex traits determined by the combination of envi-
ronmental, individual's life style and heterogenous
genetic factors and thus the contribution of each gene var-
iant is expected to be small. Recently, Yamada et al [48]
performed a large association study with 150 SNPs in 128
functionally relevant BP regulating genes for 2818 hyper-
tensive Japanese and 2035 matched controls. Using mul-
tivariable logistic regression analysis, significant
associations (0.002 < p < 0.05) with hypertension were
detected only with 10% (n = 15) of the targeted SNPs.
Interestingly, seven of these were promoter variants and in
10 SNPs out of the significant 15 the carrier status of the
minor allele provided a protective effect against blood
pressure elevation.
High homology between NAT8  and its pseudogene
NAT8B is due to a recent origin of NAT8B through the
duplication of an ancestral gene after the ape-Old World
monkey split. In chimpanzee both gene copies are still
active, whereas in human NAT8B appears to be inactive
due to human-specific nonsense mutations [49]. There
are multiple examples of gene conversion events between
genes and their pseudogenes causing the dysfunction of
the genes [50]. In case of NAT8, the alternative promoter
sequence may have arisen through gene conversion from
NAT8B leading to differentially expressed gene variants.
Although the exact function of NAT8 is still to be deter-
mined, it has recently been shown to participate in detoxi-
fication processes of TCE (trichloroethylene) metabolite
DCVC (S-(1,2-dichlorovinyl)-L-cysteine) in the kidney.
DCVC detoxification in kidneys has two alternative meta-
bolic pathways: (1) bioactivation through B-lyase activity
leading to the accumulation of a nephrotoxic reactive sulf-
hydryl-intermediate (DCVSH – dichlorovinyl mercaptan)
and (2) N-acetylation of DCVC resulting in a harmless
acetylated product (NacDCVC – N-acetyl-S-(1,2-dichlo-
rovinyl)-L-cysteine) excreted in urine [51]. When human
renal proximal tubule cells were exposed to low concen-
trations of DCVC, NAT8  expression was reduced more
than twice [15]. We hypothesize that the transcriptional
activation of the common NAT8  promoter variant is
repressible by toxic substances (e.g. TCE metabolites) and
reduction of N-acetylation activity may lead to favouringBMC Medical Genetics 2008, 9:25 http://www.biomedcentral.com/1471-2350/9/25
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of the nephrotoxic pathway. Due to differential cocktail of
activating transcription factors for the NAT8  promoter
variant with alternative SNP alleles, the minor NAT8 vari-
ant may be less sensitive to transcriptional suppression
and the carriers may be better protected for the nephrotox-
icity. The two disease processes, renal response to nephro-
toxins and the pathogenesis of hypertension may be
connected through overlapping physiological pathways. A
representative example is the enzyme haem oxigenase 1
(HO-1) responsible for the catabolism of free heam, being
induced in some models of hypertension as well as up-
regulated in a variety of kidney injury models, including
the effect of nephrotoxins (reviewed in [52]).
Conclusion
The full resequencing and pilot association study of a
novel positional candidate gene for blood pressure and
renal function, human N-acetyltransferase 8, suggested the
contribution of highly variable NAT8 promoter polymor-
phisms in determination of systolic blood pressure and
estimated glomerular filtration rate. Based on in silico
analysis, we raise the hypothesis that the alternative SNP
alleles within NAT8 upstream region may have differen-
tial effect on gene expression.
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